Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
SI-Bone ( (SIBN) ) has issued an update.
On January 12, 2026, SI-BONE announced preliminary, unaudited results indicating fourth-quarter 2025 worldwide revenue of $56.2–$56.3 million, up about 15% year on year, driven largely by U.S. revenue of $53.3–$53.4 million and an 18% increase in active U.S. physicians to roughly 1,640. For full-year 2025, worldwide revenue is expected to reach $200.8–$200.9 million, representing approximately 20% growth, with U.S. revenue of $190.9–$191.0 million growing about 21%, while cash and equivalents of roughly $147.7 million imply modest positive cash generation in the fourth quarter, underscoring solid top-line expansion and financial stability ahead of the company’s detailed earnings release expected in late February 2026.
The most recent analyst rating on (SIBN) stock is a Buy with a $28.00 price target. To see the full list of analyst forecasts on SI-Bone stock, see the SIBN Stock Forecast page.
Spark’s Take on SIBN Stock
According to Spark, TipRanks’ AI Analyst, SIBN is a Neutral.
SI-Bone’s strong revenue growth and positive earnings call outlook are significant positives, but ongoing profitability and cash flow challenges weigh on the overall score. The technical analysis supports a bullish trend, while valuation remains a concern due to negative earnings.
To see Spark’s full report on SIBN stock, click here.
More about SI-Bone
SI-BONE, Inc. (Nasdaq: SIBN), based in Santa Clara, Calif., is a global leader in developing procedural solutions for clinical challenges associated with compromised bone. Leveraging expertise in additive manufacturing, the company has built a technology platform with leading applications in sacroiliac (SI) joint fusion, adult spinal deformity and pelvic trauma, and since 2009 has supported physicians in performing more than 140,000 procedures backed by a substantial body of clinical evidence, including randomized controlled trials and over 200 peer-reviewed publications.
Average Trading Volume: 523,500
Technical Sentiment Signal: Buy
Current Market Cap: $906M
See more insights into SIBN stock on TipRanks’ Stock Analysis page.